| Glycogen storage disease type II
Nexviazyme vs Pombiliti + Opfolda
Side-by-side clinical, coverage, and cost comparison for glycogen storage disease type ii.Deep comparison between: Nexviazyme vs Pombiliti with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsPombiliti has a higher rate of injection site reactions vs Nexviazyme based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Pombiliti but not Nexviazyme, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Nexviazyme
Pombiliti
At A Glance
IV infusion
Every 2 weeks
Recombinant acid alpha-glucosidase
IV infusion
Every 2 weeks
Lysosomal acid alpha-glucosidase (GAA) replacement
Indications
- Glycogen storage disease type II
- Glycogen storage disease type II
Dosing
Glycogen storage disease type II 20 mg/kg IV every 2 weeks for patients >=30 kg; 40 mg/kg IV every 2 weeks for patients <30 kg; consider pretreatment with antihistamines, antipyretics, and/or corticosteroids to reduce infusion-associated reaction risk.
Glycogen storage disease type II 20 mg/kg actual body weight every other week as an IV infusion over approximately 4 hours, administered in combination with Opfolda, initiated approximately 1 hour after oral Opfolda.
Contraindications
—
- Pregnancy
Adverse Reactions
Most common (>5%) abdominal pain, arthralgia, chills, diarrhea, dizziness, dyspnea, erythema, fatigue, flushing, headache, hypertension, hypotension, myalgia, nausea, pruritus, pyrexia, rash, vomiting, urticaria
Serious respiratory distress, chills, pyrexia; severe hypersensitivity reactions (anaphylaxis) including chest discomfort, generalized edema, hypotension, hypoxia, tongue edema, urticaria
Most common (>=5%) Headache, diarrhea, fatigue, nausea, abdominal pain, pyrexia
Serious Anaphylaxis, urticaria
Pharmacology
Pompe disease results from deficiency of lysosomal acid alpha-glucosidase (GAA), causing intralysosomal glycogen accumulation in multiple tissues. Avalglucosidase alfa-ngpt is a recombinant human GAA engineered with high-density mannose-6-phosphate (M6P) glycans that bind M6P receptors with high affinity, enabling cellular internalization and lysosomal transport where it undergoes proteolytic activation and cleaves accumulated glycogen.
Recombinant human lysosomal acid alpha-glucosidase (rhGAA) enzyme replacement; cipaglucosidase alfa-atga binds M6P receptors via high-affinity bis-M6P moieties, is internalized into lysosomes where it undergoes proteolytic processing and cleaves accumulated glycogen; miglustat (Opfolda) stabilizes the enzyme in blood post-infusion to reduce inactivation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Nexviazyme
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Pombiliti
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (0/12)
UnitedHealthcare
Nexviazyme
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Pombiliti
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Nexviazyme
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Pombiliti
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Pompe Disease - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Pompe Disease - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
NexviazymeView full Nexviazyme profile
PombilitiView full Pombiliti profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.